- Home
- MSSA vs NSPR Comparison
MSSA vs NSPR Comparison
Compare MSSA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSSA
- NSPR
- Stock Information
- Founded
- MSSA 2021
- NSPR 2005
- Country
- MSSA United States
- NSPR Israel
- Employees
- MSSA N/A
- NSPR N/A
- Industry
- MSSA
- NSPR Medical/Dental Instruments
- Sector
- MSSA
- NSPR Health Care
- Exchange
- MSSA NYSE
- NSPR Nasdaq
- Market Cap
- MSSA 74.6M
- NSPR 63.0M
- IPO Year
- MSSA 2022
- NSPR N/A
- Fundamental
- Price
- MSSA $11.70
- NSPR $2.93
- Analyst Decision
- MSSA
- NSPR Strong Buy
- Analyst Count
- MSSA 0
- NSPR 2
- Target Price
- MSSA N/A
- NSPR $4.75
- AVG Volume (30 Days)
- MSSA 1.4K
- NSPR 78.6K
- Earning Date
- MSSA 01-01-0001
- NSPR 11-12-2024
- Dividend Yield
- MSSA N/A
- NSPR N/A
- EPS Growth
- MSSA N/A
- NSPR N/A
- EPS
- MSSA 0.19
- NSPR N/A
- Revenue
- MSSA N/A
- NSPR $6,821,000.00
- Revenue This Year
- MSSA N/A
- NSPR $13.31
- Revenue Next Year
- MSSA N/A
- NSPR $52.91
- P/E Ratio
- MSSA $61.84
- NSPR N/A
- Revenue Growth
- MSSA N/A
- NSPR 24.70
- 52 Week Low
- MSSA $10.94
- NSPR $1.81
- 52 Week High
- MSSA $14.48
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- MSSA 48.07
- NSPR 52.69
- Support Level
- MSSA $11.70
- NSPR $2.78
- Resistance Level
- MSSA $12.00
- NSPR $3.15
- Average True Range (ATR)
- MSSA 0.47
- NSPR 0.22
- MACD
- MSSA -0.02
- NSPR -0.03
- Stochastic Oscillator
- MSSA 2.14
- NSPR 47.58
About MSSA METAL SKY STAR ACQUISITION CORP
Metal Sky Star Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.